Understanding chronic symptoms and rehabilitation in LGI1 encephalitis
Official title: Antibody-mediated LGI1 Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Chronic Phase of the Disease
Run by Fundacion Clinic per a la Recerca Biomédica · NCT06515106 · Data updated 2026-11-12
This study is trying to see how a remote rehabilitation program can help people with LGI1 encephalitis who are dealing with ongoing symptoms and cognitive challenges.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Barcelona, Catalonia) |
| Status | Recruiting |
| Started | December 18, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 23, 2024 |
| Trial ID | NCT06515106 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients who have been diagnosed with antibody-mediated LGI1 encephalitis and are in the post-acute stage of the disease.
✕Probably not a fit
Patients who are unable to provide informed consent or travel to the study center may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on patients with LGI1 encephalitis, particularly those in the post-acute phase of the disease. It aims to explore the symptoms, biomarkers, and underlying mechanisms associated with the chronic phase of this autoimmune condition. Participants will engage in a remote cognitive rehabilitation program designed to address cognitive impairments resulting from the disease. The study seeks to gather data that could enhance understanding and treatment of this condition.
Why it matters
Potential benefit: If successful, this study could lead to improved cognitive rehabilitation strategies for patients suffering from LGI1 encephalitis.
How similar studies have gone: While there is ongoing research into autoimmune encephalitis, this specific approach focusing on chronic symptoms and remote rehabilitation is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Antibody-mediated LGI-1 encephalitis in the post-acute stage of the disease; * Patients has been discharged from hospital (acute phase). Exclusion Criteria: * Inability to obtain informed consent; * Inability to travel to the center.
Where it's running
-
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain Recruiting
Study contacts
- Principal investigator: Josep Dalmau, MD, PhD — Hospital Clínic
- Study coordinator: Josep Dalmau, MD,PhD
- Email: jdalmau@clinic.cat
- Phone: 34 93 227 1738
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.